Strontium ranelate containing medicinal products: risk of cardiavascular side effects
2014.05.19
Active substance: strontium ranelate
19.05.2014 - European Commission final decision
The BfArM issues information on the implementing decision of the Commission within a European safety review in accordance with Article 20 of Regulation (EC-European Community) No. 726/2004.
24.02.2014 - CHMP opinion
The BfArM issues information on the CHMP's scientific conclusions within a European safety review in accordance with Article 20 of Regulation (EC) No. 726/2004.
Further information
For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):